CD1-MR1 2025
Chairs: Giulia Casorati & Masaki Terabe
Sponsored by:
Arovella Therapeutics
CD1a-Targeted PD-1 Agonists for Localized Immunosuppression in Atopic Dermatitis (#63)
1:30 PM
Nanobodies to Leverage the MR1–MAIT Axis for Immunotherapy (#64)
1:50 PM
Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cells (#65)
2:05 PM
A protein scaffold for the facile generation of ligand-specific MR1 binders (#66)
2:20 PM